PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Linda Vidarsdottir, Alireza Azimi, Ishani Das, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, Rainer Tuominen, Olle Sangfelt, Katja Pokrovskaja Tamm, Johan Hansson, Dan Grandér, Suzanne Egyházi Brage, Per Johnsson

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)

Abstract BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy.

Externí odkaz: https://doaj.org/article/f88ae22862f24b9684552bdca23e8edf

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

Autor: Johan Falkenius, Hemming Johansson, Rainer Tuominen, Marianne Frostvik Stolt, Johan Hansson, Suzanne Egyhazi Brage

Publikováno v: BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)

Abstract Background The variable prognosis in stage III cutaneous melanoma is partially due to unknown prognostic factors. Improved prognostic tools are required to define patients with an increased risk of developing metastatic disease who might ben

Externí odkaz: https://doaj.org/article/5fa8545fb29f49a5a271587254cb505a

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma

Autor: Fernanda, Costa Svedman, Ishani, Das, Rainer, Tuominen, Eva, Darai Ramqvist, Veronica, Höiom, Suzanne, Egyhazi Brage

Publikováno v: Cancers. 14(15)

Targeted therapy (TT), together with immune checkpoint inhibitors (ICI), has significantly improved clinical outcomes for patients with advanced cutaneous malignant melanoma (CMM) during the last decade. However, the magnitude and the duration of res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a0fd15449d4949f9db274f1f79f62a2f
https://pubmed.ncbi.nlm.nih.gov/35892846

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Marianne Frostvik Stolt, Rainer Tuominen, Dan Grandér, Ishani Das, Per Johnsson, Aldwin Suryo Rahmanto, Johan Hansson, Håkan Olsson, Göran Jönsson, Sakari Kauppinen, Alireza Azimi, Christian Ingvar, Linda Vidarsdottir, Ingibjorg Sigvaldadottir, Andreas Petri, Olle Sangfelt, Katja Pokrovskaja Tamm, Suzanne Egyhazi Brage

Publikováno v: Vidarsdottir, L, Azimi, A, Das, I, Sigvaldadottir, I, Suryo Rahmanto, A, Petri, A, Kauppinen, S, Ingvar, C, Jönsson, G, Olsson, H, Frostvik Stolt, M, Tuominen, R, Sangfelt, O, Pokrovskaja Tamm, K, Hansson, J, Grandér, D, Egyházi Brage, S & Johnsson, P 2021, ' PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma ', Scientific Reports, vol. 11, no. 1, 11023 . https://doi.org/10.1038/s41598-021-89389-9
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports

BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450435b6413ba470b4e369e6f91f03c9
https://vbn.aau.dk/da/publications/4126c388-b76b-418b-bab9-cd4b3824935b

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Göran Jönsson, Katja Pokrovskaja, Marianne Frostvik-Stolt, Andreas Petri, Dan Grandér, Håkan Olsson, Sakari Kauppinen, Rainer Tuominen, Linda Vidarsdottir, Alireza Azimi, Olle Sangfelt, Per Johnsson, Johan Hansson, suzanne Egyhazi-Brage, Aldwin Suryo Rahmanto, Christian Ingvar, Ingibjorg Sigvaldadottir

Approximately 50% of human cutaneous melanomas carry activating mutations in the serine/threonine protein kinase BRAF. BRAF inhibitors (BRAFi) selectively target the oncogenic BRAFV600E/K and are effective in approximately 80% of patients carrying th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97eb6995566fafd202c10d56ebbe344e